Literature DB >> 35007234

Effects of the psychoactive compounds in green tea on risky decision-making.

Anna E Liley1, Haleigh N Joyner, Daniel B K Gabriel, Nicholas W Simon.   

Abstract

Epigallocatechin-3-gallate (EGCG) and caffeine are the two primary compounds found in green tea. While EGCG has anxiolytic and anti-inflammatory effects, its acute effects on cognition are not well understood. Furthermore, despite widespread green tea consumption, little is known about how EGCG and caffeine co-administration impacts behavior. Here, we investigated the effects of multiple doses of either EGCG or caffeine on a rat model of risk-taking. This was assessed using the risky decision-making task (RDT), in which rats choose between a small, well-tolerated reward and a large reward with escalating risk of mild footshock. Rats were tested in RDT after acute systemic administration of EGCG, caffeine or joint EGCG and caffeine. EGCG caused a dose-dependent reduction in risk-taking without affecting reward discrimination or task engagement. Caffeine did not impact risk-taking, but elevated locomotor activity and reduced task engagement at high doses. Finally, exposure to both EGCG and caffeine had no effect on risk-taking, suggesting that low-dose caffeine is sufficient to mask the risk-aversion caused by EGCG. These data suggest EGCG as a potential therapeutic treatment for psychological disorders that induce compulsive risky decision-making.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35007234      PMCID: PMC8830767          DOI: 10.1097/FBP.0000000000000664

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  66 in total

Review 1.  Examining the neurochemical underpinnings of animal models of risky choice: Methodological and analytic considerations.

Authors:  Justin R Yates
Journal:  Exp Clin Psychopharmacol       Date:  2018-12-20       Impact factor: 3.157

Review 2.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

Authors:  Brahma N Singh; Sharmila Shankar; Rakesh K Srivastava
Journal:  Biochem Pharmacol       Date:  2011-07-30       Impact factor: 5.858

Review 3.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

4.  Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG).

Authors:  Michel Vignes; Tangui Maurice; Fabien Lanté; Magali Nedjar; Karen Thethi; Janique Guiramand; Max Récasens
Journal:  Brain Res       Date:  2006-07-21       Impact factor: 3.252

5.  Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability.

Authors:  Mao-Jung Lee; Pius Maliakal; Laishun Chen; Xiaofeng Meng; Flordeliza Y Bondoc; Saileta Prabhu; George Lambert; Sandra Mohr; Chung S Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-10       Impact factor: 4.254

Review 6.  Beneficial effects of green tea--a review.

Authors:  Carmen Cabrera; Reyes Artacho; Rafael Giménez
Journal:  J Am Coll Nutr       Date:  2006-04       Impact factor: 3.169

7.  Sex differences in a rat model of risky decision making.

Authors:  Caitlin A Orsini; Markie L Willis; Ryan J Gilbert; Jennifer L Bizon; Barry Setlow
Journal:  Behav Neurosci       Date:  2015-12-14       Impact factor: 1.912

Review 8.  The safety of green tea and green tea extract consumption in adults - Results of a systematic review.

Authors:  Jiang Hu; Donna Webster; Joyce Cao; Andrew Shao
Journal:  Regul Toxicol Pharmacol       Date:  2018-03-24       Impact factor: 3.271

9.  Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats.

Authors:  Hiroko Negishi; Jin-Wen Xu; Katsumi Ikeda; Marina Njelekela; Yasuo Nara; Yukio Yamori
Journal:  J Nutr       Date:  2004-01       Impact factor: 4.798

Review 10.  DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.

Authors:  Anis Feki; Youssef Hibaoui
Journal:  Brain Sci       Date:  2018-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.